Inventiva (NASDAQ:IVA) Shares Gap Down - Here's Why

Key Points

• Inventiva S.A. (NASDAQ:IVA) experienced a gap down in share price, opening at $5.44 after closing the previous day at $5.77, and trading at $5.54.
• Equities research analysts have set new price targets for Inventiva, with Guggenheim raising their target from $9.00 to $13.00, and Piper Sandler setting a target of $26.00.
• Wealth Enhancement Advisory Services LLC increased its stake in Inventiva by 54.5%, owning 16,558 shares after a recent purchase.

Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Get Free Report)'s stock price gapped down before the market opened on Friday . The stock had previously closed at $5.77, but opened at $5.44. Inventiva shares last traded at $5.54, with a volume of 5,620 shares.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on IVA shares. Guggenheim upped their price objective on Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research note on Tuesday, September 2nd. Piper Sandler started coverage on Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 price objective on the stock. Finally, HC Wainwright started coverage on Inventiva in a research note on Wednesday, September 3rd. They set a "buy" rating and a $20.00 price objective on the stock. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $14.83.

Inventiva Trading Down 0.9%

The firm has a fifty day moving average price of $4.23 and a 200-day moving average price of $3.59.

Institutional Trading of Inventiva

A hedge fund recently bought a new stake in Inventiva stock. Wealth Enhancement Advisory Services LLC bought a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 10,715 shares of the company's stock, valued at approximately $32,000. Institutional investors and hedge funds own 19.06% of the company's stock.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.